Industry news that matters to you.  Learn more

Cardiac Biomarker ST2 Identifies Chronic Heart Failure Patients to Benefit from High-dose Beta Blocker Therapy

Reading time: 2 minutes

Critical Diagnostics, makers of the Presage® ST2 Assay, announced today that during a presentation this week at the American College of Cardiology Scientific Sessions in San Francisco, the results of a study conducted through the Massachusetts General Hospital, Circulating Concentrations of Soluble ST2 Identify Benefit of High Dose Beta Blocker in Chronic Heart Failure: Results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study, highlighted the cardiac biomarker ST2’s ability to identify those patients most likely to benefit from high-dose beta blockers and reduce risk from cardiovascular complications.

The 151 study participants were followed for 10 months and ST2 levels were measured using the Presage® ST2 Assay. Individuals with high ST2 concentrations and low beta blocker dose were more than four times as likely to result in a cardiovascular event and the least likely to survive, than those with low ST2 concentrations and high beta blocker dosage. Furthermore, ST2 levels “predicted time-to-first cardiovascular event above and beyond NT-proBNP and baseline clinical characteristics.”

“The findings of this study provide the foundation of ST2 in guiding personalized therapy for chronic heart failure patients,” notes Dr. James Snider, President of Critical Diagnostics. “ST2 is unlike any biomarker in heart failure because of its enduring prognostic strength, but now, as evidenced by the encouraging results from this study, ST2 holds the final link in potentially improving outcomes for heart failure patients through its unique ability to identify those who can benefit most from high-dose beta blocker treatment.”

“This is where the rubber meets the road in heart failure management,” exclaimed David Geliebter, Chairman and CEO of Critical Diagnostics. “While one aspect in heart failure management is to identify those patients at highest risk, it is just as important, however, if not crucial, to have the ability to measure progress in the selected treatment. ST2 continues to build evidence as the most versatile, prognostic cardiac biomarker in heart failure.”

Source: Critical Diagnostics